Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020236 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
A Phase 3 study of Multiple Myeloma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 944
- Enrollment target
- 20
- Study locations
NCT05020236 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 944 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT05020236, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 944 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Elranatamab
- DRUG Daratumumab
- DRUG Pomalidomide
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center - Aventura - Aventura
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center - Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs - Coral Springs
- University of Miami Hospital and Clinics - Deerfield Beach - Deerfield Beach
- Sylvester Comprehensive Cancer Center - Hollywood - Hollywood
- Griffin Cancer Research Building (GCRB) - Miami
- Sylvester Comprehensive Cancer Center - Miami
- University of Miami Hospital and Clinics - Miami
- Sylvester Comprehensive Cancer Center - Kendall - Miami
- Sylvester Comprehensive Cancer Center - Plantation - Plantation
California
- Clovis Community Medical Center - Clovis
- Community Cancer Institute - Clovis
- University of California San Francisco - Fresno
- Community Regional Medical Center - Fresno
Colorado
- UCHealth Poudre Valley Hospital - Fort Collins
- UCHealth Harmony - Fort Collins
- UCHealth Greeley Hospital - Greeley
- UCHealth - Medical Center of the Rockies - Loveland
Louisiana
- East Jefferson General Hospital - Metairie
New Jersey
- MSK Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 944 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05020236
The ClinicalTrials.gov registry entry for NCT05020236 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 944 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT05020236 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05020236 about?
NCT05020236 is a clinical study titled "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments". The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of el...
What is the current status of trial NCT05020236?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 944 participants. The study started on 2021-10-04. Estimated completion is 2027-05-31.
What conditions does trial NCT05020236 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05020236?
The interventions under investigation include: Dexamethasone (DRUG), Elranatamab (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT05020236?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020236 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.